Form 4: KALA BIO Director Howard B Rosen Reports Acquisition of Stock and Options

Director Howard B Rosen reports acquisition of 1,400 shares of common stock and options to purchase 3,150 shares of common stock in KALA BIO, Inc.

Summary

• Howard B Rosen, a director of KALA BIO, Inc., reported changes in beneficial ownership on June 12, 2024.
• On June 11, 2024, Rosen acquired 1,400 shares of common stock through a grant of restricted stock units (RSUs) under the company's equity incentive plan.
• Rosen also acquired an option to purchase 3,150 shares of common stock at an exercise price of $6.18.
• The RSUs and options vest on the earlier of June 11, 2025, or the date of the first annual meeting following June 11, 2024.
• Following these transactions, Rosen directly owns 13,887 shares of common stock, including 11,040 unvested RSUs.
• Rosen also indirectly owns 165 shares through the Rosen/Doherty Revocable Trust Dated 6/11/01.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The director's acquisition of shares and options suggests confidence, but it's a routine transaction.

Positives

• The acquisition of shares and options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the RSUs and stock options is contingent upon the reporting person's continued service, suggesting an incentive for continued involvement with the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company.

Stakeholder Impact

• The transactions could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by a company insider.

Key Dates